ERBB2 and head and neck squamous cell carcinoma: In vitro, HNSCCs respond to anti-HER3 antibodies, with increased response in Trop2 expressing cells.[49] Wilson et al. showed that a subset of HNSCC cell lines respond to lapatinib, a tyrosine kinase inhibitor of EGFR and HER2.